Curcumol attenuates hyperproliferation and inflammatory response in a psoriatic HaCaT keratinocyte model by inhibiting the PI3K-Akt pathway and ameliorates skin lesions and inflammatory status in psoriasis-like mice.

IF 4.6 2区医学 Q2 IMMUNOLOGY

Inflammopharmacology Pub Date : 2025-03-10 DOI:10.1007/s10787-025-01708-y

Mutian Niu, Xiaolong Li, Mingzhao Li, Fangru Chen, Hui Cao, Qingbo Liu, Bin Liang, Guangyu Pan, Chengqin Liang, Jintao Gao

{"title":"Curcumol attenuates hyperproliferation and inflammatory response in a psoriatic HaCaT keratinocyte model by inhibiting the PI3K-Akt pathway and ameliorates skin lesions and inflammatory status in psoriasis-like mice.","authors":"Mutian Niu, Xiaolong Li, Mingzhao Li, Fangru Chen, Hui Cao, Qingbo Liu, Bin Liang, Guangyu Pan, Chengqin Liang, Jintao Gao","doi":"10.1007/s10787-025-01708-y","DOIUrl":null,"url":null,"abstract":"<p><p>Psoriasis, a chronic autoimmune disorder, is characterized by keratinocyte hyperproliferation and inflammatory responses. Curcumol, a bioactive terpenoid, possesses antiproliferative and anti-inflammatory properties. This study evaluates the efficacy of curcumol in treating psoriasis in both in vitro and in vivo models. In vitro, curcumol inhibits hyperproliferation and inflammatory responses in a psoriatic HaCaT keratinocyte model stimulated by M5 cytokines by inhibiting the PI3K-Akt pathway. Additionally, in vivo, curcumol ameliorates psoriasis-like skin lesions and inflammatory status in imiquimod-induced mice. Network pharmacology revealed that curcumol's beneficial effects might involve the PI3K-Akt signaling pathway. Further investigation shows that curcumol partially counteracts the activation of PI3K-Akt by recilisib in keratinocytes. These results suggest that curcumol may be a promising therapeutic option for psoriasis.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01708-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Psoriasis, a chronic autoimmune disorder, is characterized by keratinocyte hyperproliferation and inflammatory responses. Curcumol, a bioactive terpenoid, possesses antiproliferative and anti-inflammatory properties. This study evaluates the efficacy of curcumol in treating psoriasis in both in vitro and in vivo models. In vitro, curcumol inhibits hyperproliferation and inflammatory responses in a psoriatic HaCaT keratinocyte model stimulated by M5 cytokines by inhibiting the PI3K-Akt pathway. Additionally, in vivo, curcumol ameliorates psoriasis-like skin lesions and inflammatory status in imiquimod-induced mice. Network pharmacology revealed that curcumol's beneficial effects might involve the PI3K-Akt signaling pathway. Further investigation shows that curcumol partially counteracts the activation of PI3K-Akt by recilisib in keratinocytes. These results suggest that curcumol may be a promising therapeutic option for psoriasis.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

CiteScore

8.00

自引率

3.40%

发文量

200

期刊介绍： Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]